Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ivor, Caro"'
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 11:57-66
Background: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Efalizumab, a T cell-targeted, recombinant human monoclonal antibody, is approved for the treatment of adult patients with chronic moderate to severe plaque
Autor:
Alan Menter, Patricia A. Walicke, Ivor Caro, Scott Fretzin, Kenneth B. Gordon, Steven Kempers, Bernard S. Goffe, Reni Bressinck, Kim A. Papp, Xiaolin Wang
Publikováno v:
International Journal of Dermatology. 45:605-614
Background To provide safety data for efalizumab, a recombinant humanized monoclonal IgG1 antibody, in adults with chronic plaque psoriasis. Methods A 12-week, Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled trial. At 58 stud
Autor:
Jeannie Hou, Kenneth G. Gross, Barbara M. Egbert, Leonard Harry Goldberg, Harry H. Sharata, Tiffani K. Hamilton, Ivor Caro, Howard Sofen, Benjamin Lyons
Publikováno v:
Journal of the American Academy of Dermatology. 73(1)
Background Vismodegib is approved for treatment of advanced basal cell carcinoma. Objective We sought to characterize vismodegib efficacy and safety in operable basal cell carcinoma. Methods Patients with new, operable, nodular basal cell carcinoma r
Autor:
Kim A. Papp, Charles Camisa, Alice B. Gottlieb, Xiaolin Wang, Stephen P. Stone, Ivor Caro, Patricia A. Walicke, Peter Compton
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 9:313-323
Background: The efficacy and safety of efalizumab have been evaluated in multiple clinical trials. ObjectiveThe purpose of this review is to provide an overview of the safety profile of efalizumab during the clinical trials. Methods: Twelve-week data
Autor:
Peter Compton, Ivor Caro, Steven R. Feldman, Kim A. Papp, Alice B. Gottlieb, Alan Menter, Patricia A. Walicke, Craig L. Leonardi, Kenneth B. Gordon
Publikováno v:
Journal of the American Academy of Dermatology. 52:425-433
Efalizumab inhibits multiple T-cell-mediated processes.To evaluate 12- and 24-week efalizumab therapy for psoriasis.In this phase III, randomized, double-blind trial, 498 patients received subcutaneous 1 or 2 mg/kg/wk efalizumab or placebo for 12 wee
Autor:
Ivor Caro, Artur Zembowicz
Publikováno v:
New England Journal of Medicine. 348:630-637
Presentation of Case A 16-year-old girl was admitted to the hospital because of pleuritic chest pain. Bilateral imbrication of the hip capsules had been performed 15 months earlier at this hospital because of recurrent bouts of hip dislocation. Evalu
Autor:
Kerstin Trunzer, Antoni Ribas, C. Lebbé, Dirk Schadendorf, Paul B. Chapman, Jeffrey A. Sosman, Axel Hauschild, Alessandro Testori, Omid Hamid, Paolo A. Ascierto, Grant A. McArthur, Michele Maio, John M. Kirkwood, Thomas Jouary, Brigitte Dréno, Alexander M.M. Eggermont, John B. A. G. Haanen, James Larkin, Claus Garbe, Reinhard Dummer, Ivor Caro, Ming Yin, Paul Lorigan, Stephen J O'Day, Suzanne Cheng, David Hogg, Keith T. Flaherty, Caroline Robert
Publikováno v:
The Lancet. Oncology, vol 15, iss 3
BackgroundIn the BRIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and progression in patients with advanced BRAF(V600) mutation-positive melanoma. We present an extended follow-up analysis of the total pop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377d825d8360489bb92f735b7e5e1cb4
http://hdl.handle.net/11365/1081256
http://hdl.handle.net/11365/1081256
Purpose.Vismodegib was approved for the treatment of advanced basal cell carcinoma (aBCC) based on the pivotal ERIVANCE BCC study. The primary endpoint (objective responserate[ORR])wasassessed9monthsafterthelastpatient was enrolled.To confirm the cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fcd3b03732e91b4392d2a7f4c0a516a
https://www.ncbi.nlm.nih.gov/pubmed/25001266
https://www.ncbi.nlm.nih.gov/pubmed/25001266
Autor:
Tiffani K. Hamilton, Alice B. Gottlieb, Peter Compton, Craig L. Leonardi, Paul Kwon, Ivor Caro
Publikováno v:
Journal of the American Academy of Dermatology. 54(4 Suppl 1)
Background Efalizumab is a T cell–targeted therapy for psoriasis. Objective We sought to evaluate the efficacy and safety of long-term, continuous efalizumab therapy. Methods Of 339 patients enrolled in this ongoing, open-label, phase III study, af
Autor:
Kenneth B. Gordon, Xiaolin Wang, Elyse S. Rafal, Stephen K. Tyring, Wayne Carey, Graham Wetherill, Richard G. Langley, Ivor Caro
Publikováno v:
Clinical therapeutics. 27(9)
Background: Because many therapies for psoriasis disrupt the normal inflammatory cascade and could theoretically impair the body's ability to respond to external pathogens, a possible increase in the incidence of infection is a concern with any new p